Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents

@article{Papakostas2007AreAD,
  title={Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents},
  author={George I. Papakostas and Michael E. Thase and Maurizio Fava and James Craig Nelson and Richard C. Shelton},
  journal={Biological Psychiatry},
  year={2007},
  volume={62},
  pages={1217-1227}
}
Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression
TLDR
Comparing the remission rates and time to remission in patients with major depression taking either mirtazapine or an SSRI in an all-inclusive set of studies indicates that mirtazerpine may be a more rapidly effective antidepressant than SSRIs.
Faster Onset of Antidepressant Effects of Citalopram Compared With Sertraline in Drug-Naïve First-Episode Major Depressive Disorder in a Chinese Population: A 6-Week Double-Blind, Randomized Comparative Study
TLDR
Citalopram exhibited a significantly faster onset than sertraline during the early weeks of treatment and tended to have a better efficacy in overall treatment, although the statistic was not significant.
A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode
TLDR
Significantly greater benefit for duloxetine compared with SSRIs was demonstrated on measures of pain and functioning, and study demographics suggest a more generalizable racial and ethnic population than is typical in randomized clinical trials.
Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials
TLDR
There is sufficient current evidence to suggest that patients with severe depression or those who have failed to reach remission with a SSRI may benefit from treatment with a SNRI, as large adequately powered RCTs using optimal dosing regimens and clinically relevant outcome measures in severe depression and SSRI treatment failures are still required to confirm these findings.
Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies
TLDR
This meta-analysis includes all published, randomized, double-blind, head-to-head trials, which compared venlafaxine and an SSRI in the treatment of MDD in adults, and shows that venl Lafaxine was superior to SSRIs in achieving remission and response.
S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial.
TLDR
Preliminary results suggest that SAMe can be an effective, well-tolerated, and safe adjunctive treatment strategy for SRI nonresponders with major depressive disorder and warrant replication.
Duloxetine in the acute and continuation treatment of major depressive disorder
TLDR
duloxetine is of interest in the treatment of certain conditions commonly seen in conjunction with major depression, particularly anxiety and pain, both of which may respond more favorably to agents that act on both serotonin and noradrenaline neurotransmitter systems.
Differential Antidepressant Symptom Efficacy: Placebo-Controlled Comparisons of Duloxetine and SSRIs (Fluoxetine, Paroxetine, Escitalopram)
TLDR
Potentially important differences in symptom response patterns were found between duloxetine and the combined SSRIs depending on symptom severity, and different HAMD17 items responded differently to dul oxetine compared with SSRI.
Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study
  • D. SoueryA. Serretti J. Mendlewicz
  • Psychology, Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2011
TLDR
This study supports the thesis that switching from an SSRI to a TCA (and vice versa) in non-responders to a 4-week trial of an SSri/TCA is not associated with improved response, and the result goes in the opposite direction to that predicted by current guidelines.
Everyday Problems in Treating Depression: Focus on SNRIs
TLDR
Although SNRIs clearly provide superior efficacy in certain populations, their use has not dramatically changed antidepressant therapy and the search for agents that are more effective, rapidly acting, and better tolerated continues.
...
...

References

SHOWING 1-10 OF 128 REFERENCES
A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
TLDR
The results suggest that mirtazapine and the SSRIs differ with respect to their side-effect profile but not their overall efficacy in the treatment of MDD.
A Metaanalysis of Clinical Trials Comparing Moclobemide with Selective Serotonin Reuptake Inhibitors for the Treatment of Major Depressive Disorder
  • G. PapakostasM. Fava
  • Psychology, Medicine
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2006
TLDR
It is suggested that moclobemide and the SSRIs do differ with respect to their side effect profiles but not in their overall efficacy in the treatment of MDD.
Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.
TLDR
Venlafaxine has greater efficacy than SSRIs although there is uncertainty in comparison with other antidepressants, and further studies are required to determine the clinical importance of this finding.
Pharmacogenetics of antidepressant medication intolerance.
TLDR
Pharmacodynamic differences among patients due to variant 5-HT(2A) receptors appear to be more important than pharmacokinetic variation in determining paroxetine intolerance and pharmacogenetic markers may be useful in predicting antidepressant treatment outcome.
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
TLDR
These results support the hypothesis that the S allele of 5HTTLPR at the SLC6A4 locus is associated with a poor outcome after treatment with selective serotonin reuptake inhibitors and indicate that the effect of this polymorphism on outcome may depend on the mechanism of antidepressant action.
Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine
  • G. Clerc
  • Psychology, Medicine
    International clinical psychopharmacology
  • 2001
TLDR
It is concluded that milnacipran may offer some advantages over selective serotonin reuptake inhibitors, such as fluvoxamine, in the treatment of moderate to severe major depression.
A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
TLDR
Results of this study indicate that, when titrated rapidly to their maximum recommended doses, escitalopram is at least as effective as venlafaxine XR and significantly better tolerated and do not support the hypothesis that nonselective SRIs have greater efficacy than selective SRIs.
...
...